Summary: Genmab and PDL BioPharma Have Entered into an Agreement Under Which Genmab Will Acquire PDL's Antibody Manufacturing Facility Located in
Brooklyn Park, Minnesota, USA
COPENHAGEN, Denmark and REDWOOD CITY, California, February 21 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and PDL BioPharma, Inc. (Nasdaq: PDLI) announced today that they have entered into an agreement under which Genmab would acquire PDL's antibody manufacturing facility located in Brooklyn Park, Minnesota, USA for USD 240 million to be paid in cash. The transaction also includes land, equipment and access to a leased space housing a development lab.
Genmab expects the Minnesota facility, which has a production capacity of 22,000 liters, will be sufficient to provide a sustainable source of both clinical and commercial scale material for its pipeline. The facility features two 1,000 liter and two 10,000 liter bioreactors, which support the simultaneous manufacture of multiple antibody products and will enable Genmab to transition three antibodies from research to manufacturing per year.
"Over the past few years Genmab has been preparing for the market
launch of our late stage antibodies and we continue to build a broad
pipeline of antibody products, which currently includes 10 products in
clinical development. Consequently, the need to secure significant
manufacturing capacity has become an increasing priority," stated Lisa N.
Drakeman, Ph.D., Chief Executive Officer of Genmab. "We believe that the
new PDL manufacturing facility, with its complete antibody process
development platform, represents our best option to secure manufacturing
capacity, allowing Genmab to produce antibodies more efficiently and cost
|SOURCE Genmab A/S|
Copyright©2008 PR Newswire.
All rights reserved